一季度新签订单同比增长超过30%
The company said Q1 new orders grew over 30% YoY, with small-molecule CDMO orders up over 50%.
Possible impact:May affect views on future revenue recognition and CDMO demand momentum.
康龙化成View source
企業プロフィール · Healthcare
Pharmaron Beijing Co Ltd
300759 · 深圳
その他の上場3759 · 香港株
- 取引所
- 深圳
- 国 / 地域
- China
- 従業員数
- 25,088
- 公式サイト
- www.pharmaron.com
現在値
¥38.77
リアルタイム · 2026年7月27日
妥当買付価格
≤ ¥25
安全マージンの起点
ベイリー成長スコア
55/100
標準
本源的価値 · 3 段階レンジ
現在値 ¥38.77 リアルタイム · 妥当レンジと楽観的レンジの間
現在値 ¥38.77
総合バリュエーションレンジ · 保守的 ¥22–¥25 / 妥当 ¥28–¥35 / 楽観的 ¥41–¥47。¥38.77 時点で 妥当レンジと楽観的レンジの間。
レポート公開時 ¥29.11（2026年7月3日）
Recent developments
康龙化成披露2026年一季度业绩
Q1 2026 revenue rose 15.48% to RMB3.58bn; attributable net profit rose 9.75% to RMB335m.
Possible impact:May affect expectations for full-year growth, margin resilience and order conversion.
康龙化成View source
制剂CDMO签订国际大型药企战略合作
Pharmaron said its Beijing formulation commercial facility was completed and signed a GLP-1 manufacturing partnership with a major global pharma.
Possible impact:May affect expectations for formulation CDMO commercialization capability and customer quality.
康龙化成View source
康龙化成发布2025年年度报告
2025 revenue rose 14.82% to RMB14.10bn; attributable net profit fell 7.22%, while recurring net profit rose 38.85%.
Possible impact:May affect views on core business recovery, one-off items and earnings quality.
康龙化成View source
康龙化成披露2025年年度报告
Pharmaron released its 2025 annual report covering operations, R&D spending, segment performance and cash flow.
Possible impact:May shape expectations for CRO demand, cost control and medium-term growth quality.
巨潮资讯网View source
Automatically summarized from public sources; for context only, not investment advice.
財務概要
時価総額元 707.91億
売上高（TTM）元 145.75億
EBITDA元 31.12億
純利益率11.62%
ROE9.99%
PER (TTM)40.56
予想PER32.89
EPS元 0.95
配当利回り0.51%
52週レンジ元 20.87 – 元 42.00
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
企業について
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
基礎情報
沿革
近日公開このセクションは現在準備中です。近日公開予定です。
業界での地位
近日公開このセクションは現在準備中です。近日公開予定です。
この銘柄のレポート